Page last updated: 2024-09-02

deguelin and Granulocytic Leukemia

deguelin has been researched along with Granulocytic Leukemia in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, Y; Cui, G; He, J; Wang, Y; Wen, L; Yi, S; Zhao, F; Zhao, J; Zhao, Z	1
Billi, AM; Bortul, R; Cappellini, A; Conte, R; Grafone, T; Mantovani, I; Martelli, AM; Martinelli, G; Tabellini, G; Tazzari, PL	1

Other Studies

2 other study(ies) available for deguelin and Granulocytic Leukemia

Article	Year
Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation. Annals of hematology, 2015, Volume: 94, Issue:2 Topics: Acute Disease; Apoptosis; Blotting, Western; Caspase 6; Caspase 8; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Leukemia, Myeloid; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; RNA Interference; Rotenone; Tumor Suppressor Protein p53	2015
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. British journal of haematology, 2005, Volume: 129, Issue:5 Topics: Acute Disease; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cells, Cultured; Cytarabine; Drug Resistance, Neoplasm; Erythropoietin; Etoposide; HL-60 Cells; Humans; Leukemia; Leukemia, Myeloid; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Rotenone; Signal Transduction; Stem Cell Factor; Stem Cells	2005

Article

Year

Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.

Annals of hematology, 2015, Volume: 94, Issue:2

Topics: Acute Disease; Apoptosis; Blotting, Western; Caspase 6; Caspase 8; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Leukemia, Myeloid; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; RNA Interference; Rotenone; Tumor Suppressor Protein p53

2015

Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.

British journal of haematology, 2005, Volume: 129, Issue:5

Topics: Acute Disease; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cells, Cultured; Cytarabine; Drug Resistance, Neoplasm; Erythropoietin; Etoposide; HL-60 Cells; Humans; Leukemia; Leukemia, Myeloid; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Rotenone; Signal Transduction; Stem Cell Factor; Stem Cells

2005